Rituximab in Autoimmune CNS Disease
Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Pediatric Neurology Briefs Publishers
2014-08-01
|
| Serija: | Pediatric Neurology Briefs |
| Teme: | |
| Online dostop: | https://www.pediatricneurologybriefs.com/articles/138 |